Home › Neuroblastoma › Maryland › Baltimore
Neuroblastoma clinical trials in Baltimore, MD
3 studies for Neuroblastoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RecruitingPhase 2
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- Washington, DC11 studies
- New York City, NY10 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Dallas, TX9 studies
- St. Louis, MO9 studies
- Aurora, CO8 studies
- Hartford, CT8 studies
- Minneapolis, MN8 studies
- Birmingham, AL8 studies
- Atlanta, GA7 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.